Effectiveness of High-dose Zinc Therapy and Albendazole in the Treatment of Environmental Enteropathy
This study has been completed.
Sponsor:
Washington University School of Medicine
Information provided by (Responsible Party):
Washington University School of Medicine
ClinicalTrials.gov Identifier:
NCT01440608
First received: September 22, 2011
Last updated: March 2, 2012
Last verified: March 2012
Tracking Information | |||||
---|---|---|---|---|---|
First Received Date ICMJE | September 22, 2011 | ||||
Last Updated Date | March 2, 2012 | ||||
Start Date ICMJE | October 2011 | ||||
Primary Completion Date | December 2011 (final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures ICMJE |
Changes in urine lactulose:mannitol (L:M) ratio following therapy course. [ Time Frame: 4 weeks, 7 weeks ] [ Designated as safety issue: No ] | ||||
Original Primary Outcome Measures ICMJE | Same as current | ||||
Change History | Complete list of historical versions of study NCT01440608 on ClinicalTrials.gov Archive Site | ||||
Current Secondary Outcome Measures ICMJE |
|
||||
Original Secondary Outcome Measures ICMJE | Same as current | ||||
Current Other Outcome Measures ICMJE | |||||
Original Other Outcome Measures ICMJE | |||||
Descriptive Information | |||||
Brief Title ICMJE | Effectiveness of High-dose Zinc Therapy and Albendazole in the Treatment of Environmental Enteropathy | ||||
Official Title ICMJE | Randomized, Double-blind, Placebo-controlled Trial Evaluating the Impact of High-dose Zinc Therapy and Albendazole in the Treatment of Sub-clinical Environmental Enteropathy in Rural Malawian Children | ||||
Brief Summary | The purpose of this study is to investigate the therapeutic effectiveness of high-dose zinc therapy and de-worming albendazole as separate interventions in restoring normal gut absorptive and immunological function as measured by the dual sugar permeability test and additional biomarkers in 1-3 year old rural Malawian children at high risk for Environmental Enteropathy. |
||||
Detailed Description | |||||
Study Type ICMJE | Interventional | ||||
Study Phase | |||||
Study Design ICMJE | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
||||
Condition ICMJE | Enteropathy | ||||
Intervention ICMJE |
|
||||
Study Arm (s) |
|
||||
Publications * | |||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status ICMJE | Completed | ||||
Enrollment ICMJE | 225 | ||||
Completion Date | December 2011 | ||||
Primary Completion Date | December 2011 (final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||
Gender | Both | ||||
Ages | 1 Year to 3 Years | ||||
Accepts Healthy Volunteers | Yes | ||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||
Location Countries ICMJE | Malawi | ||||
Administrative Information | |||||
NCT Number ICMJE | NCT01440608 | ||||
Other Study ID Numbers ICMJE | MJM-zincalbendazole | ||||
Has Data Monitoring Committee | |||||
Responsible Party | Washington University School of Medicine | ||||
Study Sponsor ICMJE | Washington University School of Medicine | ||||
Collaborators ICMJE | |||||
Investigators ICMJE |
|
||||
Information Provided By | Washington University School of Medicine | ||||
Verification Date | March 2012 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |